NCT05239221 - AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions

Chronic Hypoparathyroidism

Interventions

DRUG

AZP-3601

Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection

DRUG

Placebo

Saline solution visually matching active medication

Trial Locations (2)

PRA-EDS, Groningen

Amolyt Pharma Investigational Site Hungary, Budapest